The 20-fold increase (molar terms, 8-fold increase in w/v terms) in the activity upon lead optimization is strikingly similar to the improvement in cancer cell proliferation inhibition when going from first to second generation ObR antagonists (Otvos et al., 2011b,c). The gene discussed is LEPR; the disease is cancer.